About microRNA Based Diagnostic Kit
microRNA are small single-stranded RNA molecules that regulate 10–30% of all protein-coding genes. Major attributable factors in the microRNA-based diagnostic kit market include the increasing application of microRNA (miRNA) tools to diagnose neoplastic and non-neoplastic diseases and a rise in the adoption of miRNAs for target prediction, identification, and visualization. In addition, the use of microRNA signatures as potential biomarkers for patient management and increasing innovation and technological advances for detecting microRNAs in tissue and bodily fluids is driving the market growth during the forecast period.
|Unit||Value (USD Million)|
The key players are highly focused on developing and innovating new strategies such as product launches and increased R&D to maintain their market position and customer base. The companies are also planning strategic activities like partnerships, collaboration, mergers, and acquisitions to help them sustain themselves in the market and maintain their competitive edge. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global microRNA Based Diagnostic Kit market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.
TAmiRNA (Austria), Agilent Technologies (United States), Thermo Fisher Scientific Inc. (United States), Qiagen (Netherlands), Merck KGaA (Germany), NanoString (United States), HTG Molecular Diagnostics, Inc. (United States), Horizon Discovery Ltd. (United Kingdom), GeneCopoeia, Inc. (United States) and Takara Bio Inc (Japan) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are BioGenex (United States), Sistemic Scotland Limited (United States), Biodynamics Laboratory, Inc. (Greece) and Miltenyi Biotec (Germany).
AMA Research has segmented the market of Global microRNA Based Diagnostic Kit market by and Region.
On the basis of geography, the market of microRNA Based Diagnostic Kit has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Mode of Delivery, the sub-segment i.e. Conjugation will boost the microRNA Based Diagnostic Kit market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End Use, the sub-segment i.e. Hospitals and Clinics will boost the microRNA Based Diagnostic Kit market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Therapeutic Area, the sub-segment i.e. Oncology will boost the microRNA Based Diagnostic Kit market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
The surge in Prevalence of Cancer Patients
Market Growth Drivers:
Rising Incidence of Chronic Diseases such as Cancer, Rising Investments in miRNA Research & Development Initiatives and Favorable Government Initiatives and Increased Healthcare Expenditure
Challenges in Handling RNA & In-House Development of microRNA Assays
High cost associated with microRNA kits and other products
Increasing Demand for Diagnostic Testing in Hospitals
Market Leaders and their expansionary development strategies
In January 2023, Thermo Fisher Scientific Inc. completed the acquisition of The Binding Site Group, a UK-based specialist diagnostic products provider for USD 2.8 billion in cash. The Binding Site offers specialty diagnostic assays and instruments that aid in the improvement of the diagnosis and management of blood cancers and immune system disorders.
In January 2023, Qiagen launched EZ2 Connect MDx for use in diagnostic laboratories. This launch enhanced the IVD platform to carry out automated sample processing for wide-scale use. The EZ2 Connect MDx enables laboratories to purify DNA and RNA from about 24 samples in parallel in mere 30 minutes.
About ApproachTo evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.
Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.